Formulary Chapter 18: Wound Care - Full Chapter
|
Notes: |
Refer to Local Guidelines & Resources:
- County Durham & Darlington Tissue Viability Team Tel: 0191 5692970
- Northumbria Tissue Viability Service: 01670 859 030
- NuTH Tissue Viability Service: service1@nhs.net
- South Tyneside & Sunderland Tissue Viability Team: 0191 2831432
|
|
Details... |
18.01 |
Basic wound contact dressings |
|
|
18.01.01 |
Low adherence dressings |
|
|
18.01.02 |
Absorbent dressings |
|
|
18.01.02 |
For lightly exuding wounds |
|
|
18.01.02 |
For moderately to heavily exuding wounds |
|
|
18.01.02 |
For heavily exuding wounds |
|
|
18.02 |
Advanced wound dressings |
|
|
18.02.01 |
Hydrogel dressings |
|
|
18.02.01 |
Hydrogel application (amorphous) |
|
|
18.02.01 |
Hydrogel sheet dressings |
|
|
18.02.01.01 |
Sodium hyaluronate dressings |
|
|
18.02.02 |
Vapour-permeable films and membranes |
|
|
18.02.02 |
Vapour-permeable Adhesive Film Dressing (Semi-permeable Adhesive Dressing) |
|
|
18.02.02 |
Vapour-permeable Adhesive Film Dressing with absorbent pad |
|
|
18.02.02 |
For intravenous and subcutaneous catheter sites |
|
|
18.02.03 |
Soft polymer dressings |
|
|
18.02.03 |
Without absorbent pad |
|
|
18.02.03 |
With absorbent pad |
|
|
18.02.03 |
Bio-cellulose dressings |
|
|
18.02.04 |
Hydrocolloid dressings |
|
|
18.02.04 |
Without adhesive border |
|
|
18.02.04 |
With adhesive border |
|
|
18.02.04 |
Hydrocolloid-fibrous dressings |
|
|
18.02.04 |
Polyurethane matrix dressing |
|
|
18.02.05 |
Foam dressings |
|
|
18.02.05 |
For lightly exuding wounds |
|
|
18.02.05 |
For lightly to moderately exuding wounds |
|
|
18.02.05 |
For moderately to heavily exuding wounds |
|
|
18.02.06 |
Alginate dressings |
|
|
18.02.07 |
Capillary-action dressings |
|
|
18.02.08 |
Odour absorbent dressings |
|
|
18.03 |
Antimicrobial dressings |
|
|
18.03.01 |
Honey |
|
|
18.03.01 |
Sheet dressing |
|
|
18.03.01 |
Honey-based topical application |
|
|
18.03.02 |
Iodine |
|
|
18.03.03 |
Silver |
|
|
18.03.03 |
Low adherence dressings |
|
|
18.03.03 |
With charcoal |
|
|
18.03.03 |
Soft polymer dressings |
|
|
18.03.03 |
Hydrocolloid dressings |
|
|
18.03.03 |
Foam dressings |
|
|
18.03.03 |
Alginate dressings |
|
|
18.03.04 |
Other antimicrobials |
|
|
18.04 |
Specialised dressings |
|
|
18.04.01 |
Protease-modulating matrix dressings |
|
|
18.04.02 |
Silicone keloid dressings |
|
|
18.04.02 |
Silicone sheets |
|
|
18.04.02 |
Silicone gel |
|
|
18.05 |
Adjunct dressings and appliances |
|
|
18.05.01 |
Gauze and tissue |
|
|
18.05.01 |
Surgical absorbents |
|
|
18.05.01 |
Cotton |
|
|
18.05.01 |
Lint |
|
|
18.05.01 |
Pads |
|
|
18.05.02 |
Wound drainage pouches |
|
|
18.05.03 |
Physical debridement pads |
|
|
18.06 |
Complex adjunct therapies |
|
|
18.06.01 |
Topical negative pressure therapy |
|
|
18.06.01 |
Vacuum assisted closure products |
|
|
18.06.01 |
Wound drainage collection devices |
|
|
18.06.01 |
Accessories |
|
|
18.07 |
Wound care accessories |
|
|
18.07.01 |
Dressing packs |
|
|
18.07.02 |
Woven and fabric swabs |
|
|
18.07.03 |
Surgical adhesive tapes |
|
|
18.07.03 |
Permeable adhesive tapes |
|
|
18.07.03 |
Occlusive adhesive tapes |
|
|
18.07.04 |
Adhesive dressings |
|
|
18.07.04 |
Vapour permeable adhesive dressings |
|
|
18.07.05 |
Skin closure dressings |
|
|
18.07.05 |
Skin closure strips, sterile |
|
|
18.08 |
Bandages |
|
|
18.08.01 |
Non-extensible bandages |
|
|
18.08.02 |
Light-weight conforming bandages |
|
|
18.08.03 |
Tubular bandages and garments |
|
|
18.08.03 |
Elasticated |
|
|
18.08.03 |
Non-elasticated |
|
|
18.08.03 |
Silk Clothing |
|
|
18.08.04 |
Support bandages |
|
|
18.08.05 |
Adhesive bandages |
|
|
18.08.06 |
Cohesive bandages |
|
|
18.08.06 |
Cohesive extensible bandages |
|
|
18.08.07 |
Compression bandages |
|
|
18.08.07 |
High compression bandage |
|
|
18.08.07 |
Short stretch compression bandage |
|
|
18.08.07 |
Sub-compression wadding bandage |
|
|
18.08.08 |
Multi-layer compression bandaging |
|
|
18.08.08 |
Four layer systems |
|
|
18.08.08 |
Two layer systems |
|
|
18.08.09 |
Medicated bandages |
|
|
18.08.09 |
Medicated stocking |
|
|
18.09 |
Compression hosiery and garments |
|
|
18.09.01 |
Graduated compression hosiery |
|
|
18.09.01 |
Accessories |
|
|
18.09.01 |
Suspender |
|
|
18.09.01 |
Anklets |
|
|
18.09.01 |
Knee caps |
|
|
18.09.02 |
Lymphoedema garments |
|
|
|
18.10 |
Other Wound Products |
|
|
|
Other wound products not listed in BNF, but on Drug Tariff or available from NHS Supply Chain |
|
18.11 |
Skin cleansers and promotion of wound healing |
|
|
18.11.01 |
Skin cleansers and antiseptics |
|
|
18.11.07 |
Preparations for promotion of wound healing |
|
|
.... |
Key |
|
|
Cytotoxic Drug
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
Status |
Description |
|
Drugs for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician and the drug should be supplied through the hospital throughout the duration of treatment.
In some very exceptional circumstances (e.g. due to distance from the hospital, storage, supply or mobility/transport problems) it may be appropriate for the GP to be asked to prescribe a Red drug. This should be negotiated on an individual patient basis and should only be done with the GP’s prior informed agreement where the roles of the GP and hospital services are clearly defined and agreed. The GP should not feel under pressure to prescribe in these circumstances.
For all RED drugs automatically added to the formulary in response to a positive NICE TA: Prescribers need to ensure that local Trust new drug governance procedures and pharmacy processes are followed before any prescribing. |
|
Drugs initiated by hospital specialist, but where continuing treatment by GPs may be appropriate under a shared care arrangement.
The specialist should send the GP a copy of the shared care agreement to sign. The GP should sign the shared care agreement, or indicate they do not want to be part of such an agreement, and return a copy back to the specialist. Shared care guidelines are available or are being developed for most of the drugs listed as Amber.
If no shared care guideline is available, the hospital specialist should provide the patient’s GP with sufficient information and support to allow treatment to be continued and managed safely in primary care. |
|
Drugs normally recommended or initiated by a specialist (hospital or GP with an extended role https://www.rcgp.org.uk/gpwer), but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case. Provision of additional information, or an information leaflet, may be appropriate in some cases to facilitate continuing treatment by GPs. |
|
Drugs where prescribing by GPs is appropriate. Can be initiated and prescribed in all care settings, and if appropriate, discontinued without recourse to secondary care. |
|
NOT APPROVED: Drugs that have been considered by NTAG or the NENC ICB Medicines Subcommittee (or other approved body) and are not approved for prescribing within the North East and North Cumbria. |
|
UNDER REVIEW: drugs whose current formulary status or RAG status is currently under review. |
|
NOT REVIEWED: Drugs that haven not been reviewed yet. This usually means that an application is in progress. These drugs are not normally considered appropriate for prescribing in the North East and North Cumbria until such time that a decision is taken on their formulary status. |
|
|
|